pharma · Non-muscle invasive bladder cancer (NMIBC) · Low Grade Upper Tract Urothelial Carcinoma · TYRA
Tyra Biosciences
Tyra Biosciences is a pharma organization headquartered in Carlsbad, USA. It trades on NYSE under ticker TYRA. Primary therapeutic focus areas include Non-muscle invasive bladder cancer (NMIBC), Low Grade Upper Tract Uro
Carlsbad, USA HQ
93 Employees
Public company Type
TYRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carlsbad, USA
- Employees
- 93
- Programs
- 9
- Drugs
- 3
- Patents
- 17
TYR300-101
Phase 2 · other · Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
TYR300-101 for Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations is a Phase 2 program (other) at Tyra Biosciences with 1 ClinicalTrials.gov record(s).
Internal code TYR300-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tyra Biosciences
- Phase
- Phase 2
- Modality
- other
- Indication
- Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
- Status
- active
- Trials
- 1